Overview

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Status:
Active, not recruiting
Trial end date:
2025-12-25
Target enrollment:
Participant gender:
Summary
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Phase:
Phase 2
Details
Lead Sponsor:
Eye & ENT Hospital of Fudan University
Treatments:
Cetuximab